Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Leukemia. 2019 May 24;33(12):2805–2816. doi: 10.1038/s41375-019-0491-z

Figure 4. ONC212 treatment inhibits the leukemia stem and progenitor cells.

Figure 4.

(A, B) Ex vivo treatment of primary AML patient-derived xenograft (pdx) cells with ONC212. One month post-injection of pdx-AML cells with or without ONC212 (250 nM), we analyzed human CD45+ cells in peripheral blood (PB), spleen, and BM. (A) Quantification data of human CD45+ cells. Data are shown as the mean ± SD (n = 3). (B) MV4;11 cells were subcutaneously implanted in the flanks of athymic nude. Tumor volume of AML xenograft model treated with ONC201 (50 mg/kg/wk), ONC212 [(1) 5 mg/kg/wk; (2) 5 mg/kg, twice/wk; (3) 25 mg/kg, twice/wk; (4) 50 mg/kg/wk] and cytarabine (100 mg/kg, 5 times/wk). n=10, *; p < 0.05 relative to vehicle control. (D-E) NSG-S mice injected OCI-AML3-Luc were treated with or without ONC212 (treatment started on d 7, 50 mg/kg/mice, twice/wk for 7 wk). (C) Serial bioluminescence intensity of mice bearing OCI-AML3-Luc treated with the vehicle or ONC212. ONC212 treatment decreased OCI-AML3 propagation. (D) Picture of spleen from mice injected OCI-AML3-Luc with or without ONC212 treatment after 45 d of OCI-AML3-Luc cells injection. (E) Kaplan–Meier survival curves for mice (control: n = 8, ONC212: n = 11).